Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Sensorium Therapeutics Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners across 5 distinct art units. Each pending matter has its own examiner assignment, while the art-unit total indicates that at least one art unit covers more than one examiner's work.
RZECZYCKI, PHILLIP MATTHEW is the busiest examiner, with 1 pending matter. No examiner accounts for more than that reported amount, so the portfolio does not present a dominant examiner concentration. Counsel should maintain separate examiner histories and response plans for the individual matters.
The art-unit grouping offers a practical way to organize review of claim construction, prior-art issues, and prosecution timing. The available data does not establish whether matters within the same art unit share technology, claims, or substantive objections, so those connections require file-level review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (40%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| KUCHARCZK, JED A | 1 | 80.4% | +16.3% |
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799037 | THERAPEUTIC ALKALOID COMPOUNDS | HABTE, KAHSAY | — |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | KUCHARCZK, JED A | — |
| 18705706 | DEUTERATED FORMS OF ALKALOID COMPOUNDS AND THERAPEUTIC USES THEREOF | AULAKH, CHARANJIT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18806984 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18799074 | ALKYL-SUBSTITUTED DERIVATIVES OF MESEMBRINE AND MESEMBRENONE AND THERAPEUTIC USES THEREOF | BRAUN, MADELINE E | — |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1625 | 1 |
| 1623 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18806984 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103§112DP | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18799074 | ALKYL-SUBSTITUTED DERIVATIVES OF MESEMBRINE AND MESEMBRENONE AND THERAPEUTIC USES THEREOF | BRAUN, MADELINE E | 1624 | §103DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18799037 | THERAPEUTIC ALKALOID COMPOUNDS | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | KUCHARCZK, JED A | 1623 | §102 | Non-Final OA | — | Pending | May 17, 2024 |
| 18705706 | DEUTERATED FORMS OF ALKALOID COMPOUNDS AND THERAPEUTIC USES THEREOF | AULAKH, CHARANJIT | 1621 | §102 | Final Rejection | — | Pending | Apr 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSensorium Therapeutics Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Phillip Matthew Rzeczycki has the most, with 1 of Sensorium Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
